Cancer chemoprevention: Progress and promise

European Journal of Cancer

Volumn 35, Issue 13, 1999, Pages 1755-1762

  Kelloff, G J ^a   Sigman, G G ^b   Greenwald, P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

Chemoprevention; Intra epithelial neoplasia; Molecular carcinogenesis; Risk evaluation; Surrogate endpoints

Indexed keywords

CANCER INCIDENCE; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; DRUG RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0032739622     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00164-1     Document Type: Article

References (41)

1. Kelloff GJ, Hawk ET, Crowell JA, et al. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Huntington) 1996, 10, 1471-1480, 1484.
2. Kelloff GJ, Hawk ET, Karp JE, et al. Progress in clinical chemoprevention. Semin Oncol 1997, 24, 241-252.
3. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997, 278, 1073-1077.
4. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Advances Cancer Res 1999, 78, 199-334.
5. Henderson BE, Ross R, Bernstein L. Oestrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988, 48, 246-253.
6. Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998, 58, 4497-4504.
7. Miller MS, McCarver DG, Bell DA, Easton DL, Goldstein JA. Genetic polymorphisms in human drug metabolic enzymes. Fundamental Appl Toxicol 1997, 40, 1-14.
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-767.
9. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996, 56, 2488-2492.
10. Kelloff GJ, Boone CW, Steele VE, et al. Mechanistic considerations in chemopreventive drug development. J Cell Biochem 1994, (Suppl. 20), 1-24.
11. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 1998,90, 1371-1388.
12. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with a-tocopherol and -carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90, 440-446.
13. Kelloff GJ, Johnson JJ, Crowell JA, et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prevent 1995,4, 1-10.
14. Sporn MB. The war on cancer. Lancet 1996, 347, 1377-1381.
15. Schipper H, Turley EA, Baum M. A new biological framework for cancer research. Lancet 1996, 348, 1149-1151.
16. Sidransky D, Mikkelsen T, Schwechheimer K, et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992, 355, 846-847.
17. Sidransky D, Messing E. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumour suppressor genes, and growth factors. Urol Clin N Am 1992, 19, 629-639.
18. Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin of bladder cancer. NEnglJ Med 1992, 326, 737-740.
19. Rosin MP, Cairns P, Epstein JI, et al. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995, 55, 5213-5216.
20. Mao L, Schoenberg MP, Scicchitano M, et al. Detection of primary bladder cancer by microsatellite analysis. Science 1996, 271, 659-662.
21. Simoneau AR, Jones PA. Bladder cancer: the molecular progression to invasive disease. World J Urol 1994, 12, 89-95.
22. Thiberville L, Payne P, Vielkinds J, et al. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 1995, 55, 5133-5139.
23. Kishimoto Y, Sugio K, Hung JY, et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying nonsmall-cell lung cancers. J Natl Cancer Inst 1995,87, 1224-1229.
24. Larson AA, Liao S-Y, Stanbridge EJ, et al. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res 1997, 57, 4171-4176.
25. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nature Genet 1999, 21(Suppl.), 33-37.
26. Sneige N, Lagios MD, Schwarting R, et al. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Human Pathol 1999, 30, 257-262.
27. Su L-K, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in thé murine homolog of the APC gene. Science 1992, 256, 668-670.
28. Edelmann W, Yang K, Kuraguchi M, et al. Tumorigenesis in MLH1 and MLHl/Apcl638N mutant mice. Cancer Res 1999, 59, 1301-1307.
29. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the ApcM.in mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996, 56, 710-714.
30. Arbeit JM, Howley PM, Hanahan D. Chronic oestrogeninduced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sei USA 1996,93,2930-2935.
31. Matzinger SA, Grist KA, Stoner GD, et al. K-ras mutations in lung tumours from A/J and A/J X TSG-p53 Fl mice treated with 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone and phenethyl isothiocyanate. Carcinogenesis 1995, 16, 2487-2492.
32. Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997, 57, 5489-5492.
33. Reddy BS, Nayini J, Tokumo K, et al. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-a-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990, 50, 2562-2568.
34. Anzano MA, Byers SW, Smith JM, et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 1994, 54, 4614-4617.
35. Anzano MA, Peer CW, Smith JM, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1990, 88, 123-125.
36. Lucia MS, Anzano MA, Slayter MV, et al. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 1995, 55, 5621-5627.
37. Westra WH, Sidransky D. Phenotypic and genotypic disparity in premalignant lesions: of calm water and crocodiles. J Natl Cancer Inst 1998,90, 1500-1501.
38. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998,90, 1545-1551.
39. Hittelman WN, Kim HJ, Lee JS, et al. Detection of chromosome instability of tissue fields at risk: in situ hybridization. J Cell Biochem 1996, (Suppl. 25), 57-62.
40. Boone CW, Bacus JW, Bacus JV, et al. Properties of intraepithelial neoplasia relevant to cancer prevention and to the development of surrogate endpoints for clinical trials. Proc Soc Exp Med Biol 1997, 216, 151-166.
41. Kelloff GJ, Lieberman RL, Steele VE, et al. Chemoprevention of prostate cancer: concepts and strategies. Eur J Urol 1999, 35, 342-350.